ArticleMolecular cancer therapeutics2018
Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma
Open access · hybridAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 79 citations in OpenAlex.
- Oridonin ameliorates ulcerative colitis by regulating the PI3K/AKT/mTOR signaling pathway to activate autophagy.International journal of molecular medicine · 2026Article
- Article
- Targeting the NLRP3 inflammasome for inflammatory disease therapy.Trends in pharmacological sciences · 2025Review
- The anti-inflammatory effects of oridonin in resisting esophageal cancer.Frontiers in oncology · 2025Article
- An iron-based metal-organic framework nanoplatform for enhanced ferroptosis and oridonin delivery as a comprehensive antitumor strategy.Acta pharmaceutica Sinica. B · 2024Article
- Synthesis and Application of a pH-Responsive Functional Metal-Organic Framework: In Vitro Investigation for Delivery of Oridonin in Cancer Therapy.Molecules (Basel, Switzerland) · 2024Article
- Oridonin fromFood science & nutrition · 2024Review
- Dexrazoxane inhibits the growth of esophageal squamous cell carcinoma by attenuating SDCBP/MDA-9/syntenin-mediated EGFR-PI3K-Akt pathway activation.Scientific reports · 2024Article
- ThermomiR-377-3p-induced suppression of Cirbp expression is required for effective elimination of cancer cells and cancer stem-like cells by hyperthermia.Journal of experimental & clinical cancer research : CR · 2024Article
- Research Progress on the Synergistic Anti-Tumor Effect of Natural Anti-Tumor Components of Chinese Herbal Medicine Combined with Chemotherapy Drugs.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Ferroptosis-modulating small molecules for targeting drug-resistant cancer: Challenges and opportunities in manipulating redox signaling.Medicinal research reviews · 2023Review
- Discovery of Polyphenolic Natural Products as SARS-CoV-2 MPharmaceuticals (Basel, Switzerland) · 2023Article
- Case report: First case of early adenoid cystic carcinoma and squamous cell carcinoma collision cancer treated by endoscopic submucosal dissection.Frontiers in oncology · 2023Article
- Natural Products for Esophageal Cancer Therapy: From Traditional Medicine to Modern Drug Discovery.International journal of molecular sciences · 2022Review
- Role of Plant-Derived Active Constituents in Cancer Treatment and Their Mechanisms of Action.Cells · 2022Review
- Review
- Oxethazaine inhibits esophageal squamous cell carcinoma proliferation and metastasis by targeting aurora kinase A.Cell death & disease · 2022Article
- Oridonin Delays Aging Through the AKT Signaling Pathway.Frontiers in pharmacology · 2022Article
- PI3K/Akt/mTOR Signaling Pathway: Role in Esophageal Squamous Cell Carcinoma, Regulatory Mechanisms and Opportunities for Targeted Therapy.Frontiers in oncology · 2022Review
- Drug Discovery of Plausible Lead Natural Compounds That Target the Insulin Signaling Pathway: Bioinformatics Approaches.Evidence-based complementary and alternative medicine : eCAM · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 2 countries.
Mengqiu SongDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Xuejiao Liu *China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China.
Kangdong Liu *Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Ran ZhaoDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Hai HuangChina-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China.
Yuanyuan ShiChina-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China.
Man ZhangChina-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China.
Silei ZhouChina-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China.
Hua XieDivision of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Hanyong ChenThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Yin LiDepartment of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China.
Yan ZhengDepartment of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China.
Qiong WuDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Fangfang LiuDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Enmin LiDepartment of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou, Guangdong, China.
Ann M BodeThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Zigang Dong *Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China. mhyun_lee@hanmail.net zgdong@hi.umn.edu.
Mee-Hyun LeeDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China. mhyun_lee@hanmail.net zgdong@hi.umn.edu.
Zhengzhou University · CNChina-US (Henan) Hormel Cancer Institute · CNHormel (United States) · USHenan Cancer Hospital · CNShanghai Institute of Materia Medica · CNShantou University · CN
Funding
Chemoprevention of colon cancer by targeting the Wnt/beta-catenin pathwayR01CA187027 · NCI · UNIVERSITY OF MINNESOTA · PI KANG, NINGLING, ROH, EUNMIRI · 2015 to 2019
$1.7MPrevention of solar UV-induced skin cancer by targeting LTA4HR01CA196639 · NCI · UNIVERSITY OF MINNESOTA · PI LIU, LIANG · 2015 to 2019
$1.7MDeveloping new ornithine decarboxylase inhibitors to prevent skin & colon cancerR01CA166011 · NCI · UNIVERSITY OF MINNESOTA · PI DONG, ZIGANG · 2013 to 2017
$1.6MNCI NIH HHS R01 CA166011NCI NIH HHS R01 CA187027NCI NIH HHS R01 CA196639
Abstract
Overexpression or activation of AKT is very well known to control cell growth, survival, and gene expression in solid tumors. Oridonin, an inflammatory medical and diterpenoid compound isolated from
Indexed as
AnimalsApoptosisCell Line, TumorCell ProliferationDiterpenes, KauraneEsophageal Squamous Cell CarcinomaGene Expression Regulation, NeoplasticHeterocyclic Compounds, 3-RingHumansIsodonMiceOncogene Protein v-aktPlant ExtractsSignal TransductionXenograft Model Antitumor AssaysDiterpenes, KauraneHeterocyclic Compounds, 3-RingMK 2206Oncogene Protein v-aktoridoninPlant Extracts
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.